Slides
Page 1
September 23, 2026 PRESENTATION Interim OTC Deficiency Phase 2 Results and LUNAR 2.0 Next-Generation mRNA Delivery Platform
Page 2
2© 2026 Arcturus Therapeutics, Inc. Forward Looking Statements This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about: our strategy, future operations, collaborations, the likelihood of success (including safety and efficacy) and promise of our pipeline (including ARCT-810 and ARCT-2601), the planned initiation, design or completion of clinical trials, the ability to enroll subjects in clinical trials, the timing for receipt of data, the likelihood that preclinical or clinical data will be predictive of future clinical results, the likelihood that interim data or preliminary findings will be predictive of the complete data sets or final conclusions from the Phase 2 study, the likelihood that the Company will continue the Phase 2 Study or the OTC program, the likelihood that ARCT-2601 will proceed into the ongoing Phase 2 Study or any other study, the likelihood that a regulatory agency will agree with assessments of key biomarkers, the likelihood that biomarker results of ARCT-810 will lead to increased urea cycle function, the likelihood that clinical data will be sufficient to proceed into more advanced studies or for regulatory approval, the anticipated timing for regulatory submissions, the timing of, and expectations for, any results of any preclinical or clinical studies or regulatory approvals, the potential administration regimen or dosage and any statements other than statements of historical fact. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions (including the negative thereof) intended to identify forward looking statements. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward- looking statements such as the foregoing, and you should not place undue reliance on such forward-looking statements. The forward-looking statements contained or implied in this presentation are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form 10-K with the SEC and in other filings that Arcturus makes with the SEC. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Trademark Attribution: The Arcturus logo and other trademarks of Arcturus appearing in this presentation are the property of Arcturus. All other trademarks, services marks, and trade names in this presentation are the property of their respective owners.
Page 3
3© 2026 Arcturus Therapeutics, Inc. Today's Key Messages 1 ARCT-810 Clinical Evidence • Generally safe and well-tolerated across repeated dosing • ALL subjects maintained normal ammonia levels & exhibited reduction in glutamine despite generally increased protein intake 2 LUNAR 2.0 : NEW Standard in mRNA Delivery • 40× higher EPO expression vs. LUNAR 1.0, in NHPs • 38× higher OTC expression vs. the lipid used in ARCT-810, in NHPs • More protein from less mRNA improves dose and interval flexibility 3 ARCT-2601 Utilizes LUNAR 2.0 • Preliminary non-GLP package: no new findings vs. ARCT-810 • FDA has seen LUNAR 2.0 data and provided favorable advice • Plan to integrate -2601 into present ARCT-810 Phase 2 study YE 2026 4 New Platform to Impact Patients and Pipeline • Less frequent dosing, lower dose levels, shorter infusions • LUNAR 2.0 unlocks new target opportunities PKU & Gout • AI infrastructure accelerates innovation and development efficiency
Page 4
4 ARCT-810 (LUNAR-OTC) mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Page 5
Ornithine Transcarbamylase (OTC) Deficiency The most common urea cycle disorder Unmet Medical Need LUNAR-OTC Aims to Restore Enzyme Function Establishing expression of OTC enzyme in liver has potential to restore urea cycle activity to detoxify ammonia, preventing neurological damage and potentially removing need for liver transplantation The urea cycle converts neurotoxic ammonia to water-soluble urea that can be excreted in urine Deficiency in OTC causes elevated blood ammonia, which can lead to neurological damage, coma, and death Present standard of care involves a strict diet (low protein, high fluid intake) plus ammonia scavengers Present standard of care does not effectively prevent life- threatening spikes of ammonia Severe OTC Deficiency patients are referred for liver transplant, currently the only cure 10,000 prevalence in U.S./Europe 5
Page 6
ARCT-810 Clinical Trials aaaaa aa Phase 1 – Healthy Volunteers • Safe and generally well-tolerated in 24 adults Phase 1b – Single, Ascending Dose Study in OTC Deficiency Adults • 0.2 – 0.5 mg/kg in 16 adults • Safe and generally well-tolerated Phase 2 – Single Dose, Multiple Administrations, Placebo-Controlled Study in OTC Deficiency Adolescents and Adults (UK, EU) • Enrollment of 6 subjects at the 0.3 mg/kg dose level (x6 IV infusions every 2 weeks) and 2 participants with placebo • Safe and generally well-tolerated • Limited glutamine measurements suggested reduction in glutamine compared to placebo Phase 2 – Multiple doses, Multiple Administrations, Open Label Study (U.S.) • Examination of 0.3 mg/kg and 0.5 mg/kg doses (x5 IV infusions every 2 weeks) • More frequent measurements of urea cycle biomarkers and function 6 ARCT-810 has been consistently safe and well-tolerated with data suggesting improved urea cycle function
Page 7
7© 2026 Arcturus Therapeutics, Inc. U.S. Phase 2 Study Overview • Open-label, dose-ascending, multiple dose administration study • 0.3 mg/kg and 0.5 mg/kg, 5 IV infusions every 2 weeks with 4-week follow-up • Enrolled adolescents and adults with confirmed OTC deficiency • Participants directed to maintain baseline diet (e.g., protein intake) and medical management (e.g., ammonia scavenger medications) • 8 participants were enrolled across both dosing cohorts (n=4 each) All dosing has been completed with preliminary findings presented here
Page 8
8© 2026 Arcturus Therapeutics, Inc. U.S. Phase 2 Summary of Safety and Tolerability • No serious adverse events • Most treatment emergent adverse events (TEAEs) in both 0.3 mg/kg and 0.5 mg/kg dosing cohorts were mild to moderate in severity – Most common TEAEs were headache (2/8), transaminitis (2/8), and IRRs (2/8) • Both Grade 3 non-serious asymptomatic transaminitis events resolved without additional intervention after stopping study drug +One participant discontinued after a single dose of ARCT-810 due to a non-serious Grade 2 AE of IV infiltration with a subsequent Grade 2 site injection reaction. ARCT-810 was generally safe and well-tolerated following multiple dose administrations 0.3 mg/kg (N=4) 0.5 mg/kg (N=4) Participants with TEAE, n TEAE events, n 4 14 4 11 Participants with related TEAE, n Related TEAE events, n 3 8 4 8 Grade 1 Grade 2 Grade 3 3 4 + 1 6 1 1 Discontinued due to AE 1 + 0 Serious AEs, n 0 0 AESIs (hyperammonemia) 0 0 Participants with IRR, n 1 1
Page 9
9© 2026 Arcturus Therapeutics, Inc. U.S. Phase 2 Efficacy Measures • Clinically-relevant biomarkers of urea cycle – plasma ammonia and glutamine • OTC enzyme activity through urea cycle byproduct enrichment – Relative urea function (RUF) • Dietary intake – Focus on protein intake given its centrality to OTC deficiency clinical management 0.3 mg/kg (N=3+) 0.5 mg/kg (N=4) Sex n (%) F 3 (100%) F 4 (100%) Race n (%) White 3 (100%) White 4 (100%) Ethnicity (n,%) Hispanic 1 (33%) Hispanic 1 (25%) Age (yrs) Median (Range) 46 (14 – 57) 32 (17 – 42) BMI (kg/m 2) Median (Range) 24.1 (20.4 – 30.7) 23.5 (17.0 – 24.8) Nitrogen Scavengers n (%) 2 (67%) 4 (100%) Participant Baseline Characteristics +One participant discontinued after a single dose of ARCT-810 due to a non-serious Grade 2 AE of IV infiltration with a subsequent Grade 2 site injection reaction. Expansion of prior Phase 2 study measures to better understand ARCT-810’s impact on urea cycle function
Page 10
10© 2026 Arcturus Therapeutics, Inc. Changes in Clinically Relevant Biomarkers: Ammonia Objective: Stable first morning fasting plasma ammonia levels with ARCT-810 Results • 2/7 (29%) participants had elevated ammonia at baseline • At 0.3 mg/kg and 0.5 mg/kg dose levels, mean ammonia levels were similar or lower than baseline All participants achieved and maintained normal ammonia levels following ARCT-810 Points represent means ± SD of 3-4 participants. Dotted line indicates mean baseline value. +Mean difference between Day 60 (3 days after last dose) and baseline. Best available data as of 11Sep2026. -19% from baseline+ -42% from baseline+
Page 11
11© 2026 Arcturus Therapeutics, Inc. Changes in Clinically Relevant Biomarkers: Glutamine Objective: Reduction in plasma glutamine levels following ARCT-810 Results • 7/7 (100%) participants had elevated glutamine at baseline • At 0.3 mg/kg and 0.5 mg/kg dose levels, mean glutamine levels were lower than baseline All participants exhibited reduction in glutamine levels following ARCT-810 -17% from baseline+ -25% from baseline+ Points represent means ± SD of 3-4 participants. Dotted line indicates mean baseline value. +Mean difference between Day 60 (3 days after last dose) and baseline. Best available data as of 11Sep2026.
Page 12
12© 2026 Arcturus Therapeutics, Inc. Ammonia & Glutamine ARCT-810 Dose Comparison Points represent means ± SD of 3-4 participants. Best available data as of 11Sep2026. Ammonia Glutamine Consistent reductions observed at both 0.3 & 0.5 mg/kg ARCT-810 doses studied
Page 13
13© 2026 Arcturus Therapeutics, Inc. Biomarker Reductions Observed Despite Increased Protein Intake Objective: Stable protein intake (within 25% of baseline) Results • At 0.3 mg/kg and 0.5 mg/kg dose levels, mean protein intake generally increased above baseline • 5/7 (71%) participants had ≥1 timepoint that exceeded 25% baseline protein intake • All participants gained weight over course of study Increased protein intake + reductions in ammonia & glutamine suggests increased urea cycle activity Columns represent means ± SD of 3-4 participants. Best available data as of 11Sep2026.
Page 14
14© 2026 Arcturus Therapeutics, Inc. U.S. Phase 2 Study Summary • Multiple doses of ARCT-810 at both dose levels was generally safe and well- tolerated – Similar safety profiles between 0.3 mg/kg and 0.5 mg/kg • Evidence suggesting ARCT-810 increases urea cycle function – As detected by clinically-relevant biomarkers of urea cycle activity (ammonia and glutamine) • Increases in protein intake suggests ARCT-810 may allow for better protein tolerance – Important clinical outcome ARCT-810 shows good safety profile and evidence of improvements in urea cycle function
Page 15
15© 2026 Arcturus Therapeutics, Inc. Key Opinion Leader, Dr. Marshall Summar Marshall Summar, M.D., Former founding member and Executive Committee member of the NIH UCD Consortium, a recognized expert in rare diseases and OTC deficiency, will participate in the presentation. • Previously Chief of the Division of Genetics and Metabolism, Director of the Rare Disease Institute and the Margaret O’Malley Chair of Genetic Medicine at Children’s National Hospital, Emeritus Professor of Pediatrics at George Washington University. Dr . Summar is an internationally recognized expert in urea cycle disorders (UCDs) with over four decades of clinical, research, and policy leadership. He is a founding member and Executive Committee member of the NIH UCD Consortium, where he led national UCD diagnostic and treatment consensus efforts. For more than 20 years, he served on the Scientific Advisory Board of the National UCD Foundation and has advised numerous academic and industry initiatives. He is the author of over 40 UCD-related publications, including GeneReviews®, clinical guidelines, and multinational natural history studies. As an inventor, he holds patents for ammonia diagnostics and UCD-related technologies and has led translational research in critical care and neonatal disease. In recognition of his long-standing contributions to rare disease research and clinical infrastructure, he received the National Organization for Rare Disorders Lifetime Achievement Award in 2022
Page 16
16© 2026 Arcturus Therapeutics, Inc. KOL Perspective: ARCT-810 Phase 2 Data • The glutamine result is what persuades a metabolic physician: elevated in every participant despite mostly normal ammonias, down in every participant on drug, and back toward baseline once dosing stopped. That is drug effect, not variability. • The clear ammonia decline in the 0.5 mg/kg cohort was a surprise: these were stable patients on unchanged scavenger doses, where a flat line is the expected result. • Adoption should be brisk rather than cautious: the safety profile is clean and the biochemistry is legible to treating physicians, so I would expect 25% or more of eligible patients to be early adopters. ARCT-810 is safe, tolerated, and effective, and the treating community is prepared to use it
Page 17
ADVANCES IN LUNAR DELIVERY PLATFORM LUNAR 2.0TM
Page 18
18© 2026 Arcturus Therapeutics, Inc. ApoE carries the particle to the hepatocyte — but escaping the endosome is where the pathway is lost How IV mRNA–LNP Medicines Work RATE-LIMITING STEP most is degraded in the lysosome Four-lipid particle An ionizable lipid, DSPC, cholesterol and PEG–lipid encapsulate the mRNA. ApoE corona forms After IV dosing the PEG sheds and plasma ApoE adsorbs onto the surface. Hepatocyte uptake ApoE binds LDLR on the hepatocyte and the particle enters by endocytosis. Endosomal escape The endosome acidifies, the ionizable lipid protonates and mRNA is released to the ribosomes — but most of it never gets out. Endosomal escape is bottleneck — only ~2-5% of internalized mRNA reaches the ribosome
Page 19
19© 2026 Arcturus Therapeutics, Inc. Lipid Fold Enhancement Over LUNAR 1.0 ALC-315 2.2 ATX-126 (Lipid in KOSTAIVE®) 14 ATX-2 (LUNAR 1.0) 1.0 LUNAR 2.0 40 Relative Fold Enhancement in Human EPO Protein Expression ALC-315 ATX-126 (Lipid in KOSTAIVE*) ATX-2 (LUNAR 1.0) LUNAR 2.0 0 10 20 30 40 50 60 hEPO Expression Fold over LUNAR 1.0 lipid 0.3 mg/Kg 40X LUNAR 2.0 produced 40-fold higher hEPO expression in NHPs compared to LUNAR 1.0 Next Generation LNP: 40-Fold Higher Expression • NHPs (n=3) treated, IV 60-min infusion @ 0.3 mg/kg) • Plasma concentration 48 hours post infusion • Only the ionizable lipid differs between arms — same hEPO mRNA, same dose, same infusion LUNAR 2.0
Page 20
20© 2026 Arcturus Therapeutics, Inc. ARCT-2601 Highly Effective in OTC-Deficient Model Survival in OTC -deficient mice on a high- protein diet LUNAR 2.0 0 7 14 21 28 35 42 49 56 T im e (D a y s ) Sur vi vi ng Ani m al s ( % ) Hi gh Pr ot ei n Di et ( Cont r ol ) , n=10 LU N AR- O TC 0. 3 m g/kg, n=10 LU N AR- O TC 1 m g/ kg, n=10 0 10 20 30 40 50 60 70 80 90 100 LU N AR - O TC I . V. D osi ng Schedul e 0. 3 m g/ kg 1 m g/kg Cont r ol 0 7 14 21 28 35 42 49 56 63 70 10 20 30 40 50 60 70 80 90 100 % Survival PBS LUNAR 2.0-hOTC 0.1mg/kg LUNAR 2.0-hOTC 0.3mg/kg 0 Dose #1Dose #2Dose #3Dose #4Dose #5 ⋇High Protein Diet Started Day 3 Post First Dose Time (days) Control ARCT-2601 (LUNAR-OTC 2.0) treatment exhibits dose-dependent survival in lethal OTCD murine model ARCT-2601 utilizes LUNAR 2.0 ARCT-810 utilizes ATX-95
Page 21
21© 2026 Arcturus Therapeutics, Inc. ARCT-2601: 38-Fold Higher hOTC Expression in NHP compared to ATX-95 (Lipid in ARCT-810) • NHPs (n=3) treated, and PBS control; IV 60-min infusion @ 0.3 mg/kg • Liver biopsies 48h post-infusion analyzed for hOTC via mass spec LUNAR 2.0 exhibits 38-fold higher hOTC expression in NHPs compared to ATX-95 (Lipid in ARCT-810) Lipid Fold Enhancement Over ATX-95 ALC-315 5.3 SM-102 2.5 ATX-95 (used in ARCT-810) 1.0 LUNAR 2.0 (used in ARCT-2601) 38 Relative Fold Enhancement in Human OTC Protein Expression ALC-315 SM-102 ATX-95 LUNAR 2.0 0 10 20 30 40 50 60 hOTC Expression Fold Change 0.3 mg/kg ~38X LUNAR 2.0
Page 22
22© 2026 Arcturus Therapeutics, Inc. Three non-GLP preclinical studies, head-to-head against ARCT-810: no new findings ARCT-2601 (LUNAR-OTC 2.0) Preliminary Safety Data No new safety signals vs. ARCT-810 — and the new LUNAR 2.0 lipid clears faster ARCT-2601 LUNAR-OTC 2.0 ARCT-810 LUNAR-OTC RODENT SAFETY STUDY · NON- GLP No new findings versus ARCT-810 NHP TOLERABILITY STUDY · NON -GLP No new findings versus ARCT-810 BIODISTRIBUTION New LUNAR 2.0 lipid clears faster
Page 23
23© 2026 Arcturus Therapeutics, Inc. ARCT-2601: FDA Feedback and Regulatory Plan ARCT-2601 to be integrated into ongoing Phase 2 study as advised by the FDA FDA Type C Meeting on ARCT-2601 Development: Conducted June 2026 • FDA agreed to leverage platform CMC, non-clinical and clinical data to accelerate the development • FDA agreed to include ARCT-2601 as an arm in the current ongoing ARCT-810 Phase 2 study • Evaluate preliminary safety, PK, and biomarker data for ARCT-2601 in a small number of patients • Proceed to an adequate and well-controlled pivotal trial if the initial data are favorable ARCT-2601 Regulatory / Clinical Plan • IND Filing 4Q 2026: Evaluate ARCT-2601 in ongoing ARCT-810 Phase 2 study with 3–6 patients o Ages ≥12, with elevated baseline ammonia levels • Advance to a Phase 2/3 pediatric study in H2 2027 o Ages 0–6, neonatal-onset and severe late-onset patients with unmet medical needs
Page 24
© 2026 Arcturus Therapeutics, Inc. 24 LUNAR 2.0 – Opens Door to Reduced Infusion Time Better LNP potency × higher concentration → collapses dose volume → collapses clinic time CURRENT 3 Hours infusion time VOLUME 250 mL DOSE 0.5 mg/kg PROPOSED — NEAR TERM 1 Hour infusion time VOLUME 40 mL DOSE 0.3 mg/kg FUTURE — SYRINGE PUMP < 5 Min infusion time VOLUME 5 mL DOSE 0.15 mg/kg 36× shorter clinic time (3 hr → 5 min) 50× lower infusion volume (250 mL → 5 mL) 7× fewer drug product vials (7 vials → 1 vial) RTU ready-to-use (no dilution required) The Challenge: mRNA-LNP therapeutics targeting the liver must be infused IV
Page 25
25© 2026 Arcturus Therapeutics, Inc. Engineering mRNA Therapeutics with AI Arcturus’ differentiated computational engine improves design quality, accelerates development, and de-risks pipeline 1 WHAT WE ACQUIRE Published algorithms, a live platform, and the team behind them Validated algorithms neoMS presentation and neoIM immunogenicity prediction — published, peer-reviewed Platform in production Ten AI modules on one IVD-ready ImmunoEngine workflow, live with pharma partners The team behind it Ghent computational immunology group — a capability we would spend years hiring into San Diego Advanced Prediction 2 WHAT ARCTURUS GAINS Better candidates, designed faster and with fewer wasted cycles mRNA & construct design myRNA and myCONSTRUCT into LUNAR and STARR Immunogenicity risk myADA and myEPITOPE screening on expressed protein payloads Targets beyond oncology myPATHOGEN, mySELF and mySURFACE seed starts Translational data myINSIGHTS for biomarker discovery and response prediction Speed • Quality • Efficiency 3 WHERE IT SHOWS UP FIRST PKU and Gout demonstrate the near- term application Screen before selection Epitope and ADA-risk screening pre-selection PKU Protein replacement where ADA risk is primary Gout Expressed enzyme payload with the same immune exposure Portfolio read-through Extends to every expressed protein payload in the portfolio PKU | Gout Arcturus AI infrastructure accelerates innovation across mRNA therapeutic pipeline
Page 26
26© 2026 Arcturus Therapeutics, Inc. Expansion of Liver Disease Franchise: PKU LUNAR-PKU: Arcturus’s strategy to treat phenylketonuria (PKU) 1 DISEASE BACKGROUND PKU is a rare inborn error of metabolism Phenylketonuria results from defective phenylalanine (Phe) metabolism caused by mutations in the enzyme phenylalanine hydroxylase (PAH). Rare IEM | PAH mutation 2 THERAPEUTIC APPROACH IV-administered mRNA restores PAH activity mRNA encoding the PAH enzyme replaces deficient or defective intracellular enzyme activity in patients with PKU. mRNA-encoded PAH 3 DELIVERY PLATFORM LUNAR 2.0 LNP delivers mRNA to the liver LUNAR 2.0 increased potency combined with mRNA modification enables efficient hepatocyte delivery and franchise expansion into PKU. LUNAR 2.0 | Hepatocyte delivery LUNAR 2.0 potency plus mRNA modification enable expansion into PKU, a liver disease with high unmet need
Page 27
27© 2026 Arcturus Therapeutics, Inc. Why PKU Now? Two-Stage Platform Optimization Story From 24 hours → 6-7 days durability through mRNA + LNP engineering STAGE 1 · Arcturus mRNA Optimization STAGE 2 · PAH Protein Expression in NHP Liver Optimized mRNA + LUNAR 2.0 lipid leads to robust protein expression in NHP liver at day 2 & day 7 post-IV dose 6-7 days efficacy with improved PAH mRNA Optimized PAH Expression in NHP Liver Single-Dose Durability Achieved Via Coordinated mRNA + LNP Optimization 0 1 2 3 4 5 6 7 0.0 0.2 0.4 0.6 0.8 1.0 2 4 PAH mRNA-LNPs 1 mg/kg i.v. in PKU Mice Days Post-Dose Plasma Phe (mM) ARCT mRNA Gen 1 Published PAH Sequence ARCT mRNA Gen 3 ARCT mRNA Gen 4 ARCT mRNA Gen 2
Page 28
28© 2026 Arcturus Therapeutics, Inc. Gout is a Disease Caused by a Missing Enzyme Humans lost the gene to make uricase ~15 million years ago Mammals: uricase ON Uric acid is dissolved and excreted Humans: gene switched OFF Uric acid builds up → crystals in joints → gout Arcturus: mRNA turns it back ON The liver makes uricase, restores ability to excrete uric acid Serum uric acid, mg/dL Most mammals 0.5–2 Healthy human 3.5–7 Gout patient >8 0 2 4 6 8 10 6.8 · crystals form 9.2M U.S. gout patients 200K fail every oral drug $13.5B uricase market by 2034 Restoring uricase is restoring native biology — a liver-expressed enzyme delivered by LUNAR 2.0
Page 29
29© 2026 Arcturus Therapeutics, Inc. Key Takeaways 1 POTENCY > 30X Improvement higher liver protein expression than LUNAR 1.0 in NHP 2 ARCT -2601 (OTC Deficiency) Phase 2: YE 2026 Highly potent in NHPs, no new preclinical safety signals; FDA-aligned to integrate ARCT-2601 into present ARCT-810 Phase 2 study 3 FUTURE PATIENT CONVENIENCE Lower Dose → < 5 Min 4 FRANCHISE EXPANSION PKU · Gout LUNAR 2.0 + engineered mRNA open the next liver indications More protein from less mRNA — lower doses, shorter infusions, new indications LUNAR 2.0
Page 30
30© 2026 Arcturus Therapeutics, Inc. KOL Perspective: The LUNAR 2.0 Platform and ARCT-2601 • A greater than 30-fold potency gain is a change in kind, not degree: it moves the objective from supporting the urea cycle to correcting it, and it buys headroom on both dose and interval. • Once-monthly dosing is the variable that determines real-world benefit: in a disease of daily vigilance, interval drives enzyme persistence, and persistence is what changes outcomes. • I expect ARCT-2601 to become the standard of care, particularly in severe onset OTC deficiency, and the same platform reads through to a long list of liver-based rare diseases, where roughly 70% of patients are children. Even if gene editing reaches it’s promise patients will still need a significant treatment window and to date edited patients have still required pharmacologic support. ARCT-2601 should set the standard in OTC deficiency and extend well beyond it
Page 31
31© 2026 Arcturus Therapeutics, Inc. Q & A